TABLE OF CONTENTS
1 INTRODUCTION 14
1.1 OBJECTIVES OF THE STUDY 14
1.2 MARKET DEFINITION 14
1.3 OVERVIEW OF THE NORTH AMERICA HEREDITARY CANCER TESTING MARKET 14
1.4 CURRENCY AND PRICING 16
1.5 LIMITATIONS 16
1.6 MARKETS COVERED 17
2 MARKET SEGMENTATION 20
2.1 MARKETS COVERED 20
2.2 GEOGRAPHICAL SCOPE 21
2.3 YEARS CONSIDERED FOR THE STUDY 22
2.4 DBMR TRIPOD DATA VALIDATION MODEL 23
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 26
2.6 MULTIVARIATE MODELLING 27
2.7 MARKET END USER COVERAGE GRID 28
2.8 SOURCE LIFELINE CURVE 29
2.9 DBMR MARKET POSITION GRID 30
2.10 VENDOR SHARE ANALYSIS 32
2.11 SECONDARY SOURCES 33
2.12 ASSUMPTIONS 33
3 EXECUTIVE SUMMARY 34
4 PREMIUM INSIGHT 37
4.1 PESTEL ANALYSIS 38
4.2 PORTERS FIVE FORCES 39
5 NORTH AMERICA HEREDITARY CANCER TESTING MARKET: REGULATIONS 40
6 MARKET OVERVIEW 45
6.1 DRIVERS 47
6.1.1 RISING INCIDENCE OF HEREDITARY CANCER 47
6.1.2 INCREASE IN THE GERIATRIC POPULATION 47
6.1.3 RISING HEALTHCARE SPENDING 48
6.1.4 INCREASE IN AWARENESS ABOUT CANCER TESTING 48
6.2 RESTRAINTS 49
6.2.1 HIGH COST OF HEREDITARY CANCER TESTING 49
6.2.2 LACK OF SKILLED PROFESSIONALS 50
6.3 OPPORTUNITIES 50
6.3.1 STRATEGIC INITIATIVES BY MARKET PLAYERS 50
6.3.2 INCREASED DEMAND FOR NON-INVASIVE TESTING METHODS 51
6.3.3 GROWING DEMAND FOR BETTER QUALITY HEALTHCARE AND EARLY DIAGNOSIS 52
6.3.4 TECHNOLOGICAL DEVELOPMENTS IN HEREDITARY CANCER TESTING PROCEDURES 52
6.4 CHALLENGES 53
6.4.1 ETHICAL CHALLENGES FACED DURING HEREDITARY CANCER TESTING 53
6.4.2 RISING COMPETITION AMONG MARKET PLAYERS 54
7 NORTH AMERICA HEREDITARY CANCER TESTING MARKET, BY TEST TYPE 55
7.1 OVERVIEW 56
7.2 MULTI PANEL TEST 59
7.3 SINGLE-SITE GENETIC TEST 59
8 NORTH AMERICA HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE 60
8.1 OVERVIEW 61
8.2 BIOPSY 64
8.2.1 NEEDLE BIOPSIES 64
8.2.2 ENDOSCOPIC BIOPSIES 64
8.2.3 LAPAROSCOPIC, THORACOSCOPIC, AND MEDIASTINOSCOPIC BIOPSY 65
8.2.4 LAPAROTOMY AND THORACOTOMY 65
8.2.5 OTHERS 65
8.3 IMAGING 65
8.3.1 MAGNETIC RESONANCE IMAGING (MRI) 66
8.3.2 COMPUTED TOMOGRAPHY (CT) SCAN 66
8.3.3 POSITRON EMISSION TOMOGRAPHY (PET) SCAN 66
8.3.4 NUCLEAR SCAN 66
8.3.5 ULTRASOUND 66
8.3.6 X-RAYS 66
8.4 LAB TESTS 67
8.4.1 BLOOD 67
8.4.2 URINE 67
8.4.3 OTHERS 67
9 NORTH AMERICA HEREDITARY CANCER TESTING MARKET, BY TECHNOLOGY 68
9.1 OVERVIEW 69
9.2 POLYMERASE CHAIN REACTION (PCR) 72
9.3 SEQUENCING 72
9.4 MICRO ARRAY 73
10 NORTH AMERICA HEREDITARY CANCER TESTING MARKET, BY DISEASE TYPE 74
10.1 OVERVIEW 75
10.2 HEREDITARY BREAST & OVARIAN CANCER SYNDROME 78
10.3 COWDEN SYNDROME 78
10.4 LYNCH SYNDROME 79
10.5 HEREDITARY LEUKEMIA AND HEMATOLOGIC MALIGNANCIES SYNDROME 79
10.6 FAMILIAL ADENOMATOUS POLYPOSIS (FAP) 80
10.7 LI-FRAUMENI SYNDROME 80
10.8 VON HIPPEL-LINDAU DISEASE 81
10.9 MULTIPLE ENDOCRINE NEOPLASIAS (MEN) SYNDROME 81
11 NORTH AMERICA HEREDITARY CANCER TESTING MARKET, BY END USER 82
11.1 OVERVIEW 83
11.2 HOSPITALS 86
11.3 CLINICS 86
11.4 DIAGNOSTIC CENTERS 87
11.5 RADIOLOGY CENTERS 87
11.6 LABORATORIES 88
11.7 OTHERS 88
12 NORTH AMERICA HEREDITARY CANCER TESTING MARKET, BY DISTRIBUTION CHANNEL 89
12.1 OVERVIEW 90
12.2 DIRECT TENDER 93
12.3 RETAIL SALES 93
13 NORTH AMERICA HEREDITARY CANCER TESTING MARKET, BY REGION 94
13.1 NORTH AMERICA 95
13.1.1 U.S. 102
13.1.2 CANADA 106
13.1.3 MEXICO 110
14 NORTH AMERICA HEREDITARY CANCER TESTING MARKET: COMPANY LANDSCAPE 114
14.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 114
15 SWOT ANALYSIS 115
16 COMPANY PROFILE 116
16.1 ABBOTT 116
16.1.1 COMPANY SNAPSHOT 116
16.1.2 REVENUE ANALYSIS 116
16.1.3 COMPANY SHARE ANALYSIS 117
16.1.4 PRODUCT PORTFOLIO 117
16.1.5 RECENT DEVELOPMENTS 117
16.2 ILLUMINA, INC. (2021) 118
16.2.1 COMPANY SNAPSHOT 118
16.2.2 REVENUE ANALYSIS 118
16.2.3 COMPANY SHARE ANALYSIS 119
16.2.4 PRODUCT PORTFOLIO 119
16.2.5 RECENT DEVELOPMENTS 120
16.3 PERKINELMER INC. (2021) 121
16.3.1 COMPANY SNAPSHOT 121
16.3.2 REVENUE ANALYSIS 121
16.3.3 COMPANY SHARE ANALYSIS 122
16.3.4 PRODUCT PORTFOLIO 122
16.3.5 RECENT DEVELOPMENTS 122
16.4 LIFELABS GENETICS 123
16.4.1 COMPANY SNAPSHOT 123
16.4.2 COMPANY SHARE ANALYSIS 123
16.4.3 PRODUCT PORTFOLIO 124
16.4.4 RECENT DEVELOPMENTS 124
16.5 EUROFINS SCIENTIFIC (2021) 125
16.5.1 COMPANY SNAPSHOT 125
16.5.2 REVENUE ANALYSIS 125
16.5.3 COMPANY SHARE ANALYSIS 126
16.5.4 PRODUCT PORTFOLIO 126
16.5.5 RECENT DEVELOPMENT 126
16.6 AMBRY GENETICS 127
16.6.1 COMPANY SNAPSHOT 127
16.6.2 REVENUE ANALYSIS 127
16.6.3 PRODUCT PORTFOLIO 128
16.6.4 RECENT DEVELOPMENTS 128
16.7 BIOCARTIS 129
16.7.1 COMPANY SNAPSHOT 129
16.7.2 REVENUE ANALYSIS 129
16.7.3 PRODUCT PORTFOLIO 130
16.7.4 RECENT DEVELOPMENTS 130
16.8 BIO-HELIX 131
16.8.1 COMPANY SNAPSHOT 131
16.8.2 PRODUCT PORTFOLIO 131
16.8.3 RECENT DEVELOPMENTS 131
16.9 BIOREFERENCE (A SUBSIDIARY OF OPKO HEALTH, INC.) (2021) 132
16.9.1 COMPANY SNAPSHOT 132
16.9.2 REVENUE ANALYSIS 132
16.9.3 PRODUCT PORTFOLIO 133
16.9.4 RECENT DEVELOPMENT 133
16.10 CENTOGENE N.V. (2021) 134
16.10.1 COMPANY SNAPSHOT 134
16.10.2 REVENUE ANALYSIS 134
16.10.3 PRODUCT PORTFOLIO 135
16.10.4 RECENT DEVELOPMENT 135
16.11 CEPHEID 136
16.11.1 COMPANY SNAPSHOT 136
16.11.2 PRODUCT PORTFOLIO 136
16.11.3 RECENT DEVELOPMENT 136
16.12 FULGENT GENETICS 137
16.12.1 COMPANY SNAPSHOT 137
16.12.2 REVENUE ANALYSIS 137
16.12.3 PRODUCT PORTFOLIO 138
16.12.4 RECENT DEVELOPMENT 138
16.13 INVITAE CORPORATION 139
16.13.1 COMPANY SNAPSHOT 139
16.13.2 REVENUE ANALYSIS 139
16.13.3 PRODUCT PORTFOLIO 140
16.13.4 RECENT DEVELOPMENT 140
16.14 NATERA, INC. (2021) 141
16.14.1 COMPANY SNAPSHOT 141
16.14.2 REVENUE ANALYSIS 141
16.14.3 PRODUCT PORTFOLIO 142
16.14.4 RECENT DEVELOPMENTS 142
16.15 4BASECARE. 144
16.15.1 COMPANY SNAPSHOT 144
16.15.2 PRODUCT PORTFOLIO 144
16.15.3 RECENT DEVELOPMENTS 145
17 QUESTIONNAIRE 146
18 RELATED REPORTS 149

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.